Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)

By sjmartinez • August 16, 2023

Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Bengtsson T, Rickard K, Sciurba F. Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials). Am J Respir Crit Care Med. 2023 Aug 15;208(4):406-416. doi: 10.1164/rccm.202306-0944OC. PMID: 37364283.

Tags: COPD, dual PDE3 and PDE4 inhibitor, ensifentrine, nebulized therapy, Publications, Pulmonary, Critical Care & Sleep Medicine

Related Posts

Integrating long-acting injectable cabotegravir for HIV prevention into the Brazilian public health system ImPrEP CAB Brasil: a hybrid type-2 implementation-effectiveness cohort study

Grinsztejn B, Torres TS, Hoagland B, Coutinho C, Silva MST, Leite IC, Cunha M, Derrico M, Jalil EM, Cardoso SW, Trefiglio R, Farias A, Mourão[...]

Getting to best practice: a practice-oriented checklist for monitoring clinic-level fidelity to hypertension interventions in a large safety-net healthcare system

Korn AR, Gandhi P, R Dopp A, Barron J, Casillas-Salazar R, Durant C, G Morales M, Norwood-Scott E, L Carson S, Casillas A, B Hamilton[...]

Air Pollution Triggers Metabolomic Signature of Mitochondrial Dysfunction in Mice and Humans: Implications for Cardiovascular Disease Development

Lin Y, Qiu X, Gupta R, Ramanathan G, Lu X, Yin F, Fiehn O, Zhang JJ, Kaufman JD, Zhu Y, Rosenfeld M, Araujo JA. Air[...]